Enterprise Therapeutics Granted EMA Orphan Medicinal Product Designation for Novel Cystic Fibrosis Therapy, ETD001

BRIGHTON, England–(BUSINESS WIRE)–Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted ETD001 designation as an orphan medicinal product for the treatment of cystic fibrosis. This follows the announcement earlier this year of a positive Phase 2

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.